Latigo Biotherapeutics, Inc.
Public company- Headquarters
- THOUSAND OAKS, California
- Ticker
- LTGO
- CIK
- 0002056611
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CEOTodd Smith | Nov 5, 2026 | Appointed |
| member of the BoardNima Farzan | Nov 5, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
CEO appointed: Todd Smith
Todd Smith was named President and Chief Executive Officer of Latigo Biotherapeutics, Inc., effective November 3, 2026. Todd Smith succeeds Nima Farzan. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 5, 2026Role: President and Chief Executive Officer
- Executive departure
CEO departs: Nima Farzan
Nima Farzan, President and Chief Executive Officer of Latigo Biotherapeutics, Inc., departs the role, effective November 3, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 5, 2026Role: President and Chief Executive Officer
- Executive departure
member of the Board departs: Nima Farzan
Nima Farzan, member of the Board of Latigo Biotherapeutics, Inc., resigns the role, effective November 3, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 5, 2026Role: member of the Board
Last verified Nov 8, 2026